Endocan and Lumican in Relation to Cardiometabolic Risk in a Pediatric Overweight and Obese Cohort: A Cross-Sectional Study

The aim of the study was to evaluate serum Endocan and Lumican levels as biomarkers for pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and to explore their associations with pediatric cardiometabolic risk factors. We conducted a cross-sectional study on 68 pediatric obese and overweight (O&O...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2020, Vol.2020 (2020), p.1-11
Main Authors: Bălănescu, Paul, Bălănescu, Eugenia, Stan, Iustina Violeta, Comanici, Valentina Daniela, Codreanu, Ioana Florentina, Bălănescu, Anca
Format: Article
Language:English
Subjects:
Biomarkers
Blood pressure
Body mass index
Body weight
Chronic illnesses
Cross-sectional studies
Fatty liver
Health risks
Hypertension
Insulin resistance
Liver diseases
Metabolic disorders
Metabolic syndrome
Obesity
Obesity in children
Overweight
Pediatrics
Physiological aspects
Risk analysis
Risk factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of the study was to evaluate serum Endocan and Lumican levels as biomarkers for pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and to explore their associations with pediatric cardiometabolic risk factors. We conducted a cross-sectional study on 68 pediatric obese and overweight (O&O) patients. Ten healthy controls were recruited. Serum Lumican and Endocan levels were analyzed using ELISA kits. O&O patients had lower levels of Endocan compared to healthy controls (p
ISSN:2314-6133
2314-6141
DOI:10.1155/2020/2102401